| Autor: |
Civelek E; Istanbul University Faculty of Pharmacy, Department of Pharmacology, Istanbul, Turkey.; Istanbul University, Graduate School of Health Sciences, Istanbul, Turkey; erkan.civelek@istanbul.edu.tr., Karaman EF; Istanbul University Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul, Turkey.; Biruni University Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul, Turkey; ecemfatmakaraman@gmail.com., Ozden S; Istanbul University Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul, Turkey; stopuz@istanbul.edu.tr., Büyükpınarbaşılı N; Bezmialem Vakif University Faculty of Medicine, Department of Medical Pathology, Istanbul, Turkey; nurbuyukpinar@hotmail.com., Uydeş Doğan BS; Istanbul University, Faculty of Pharmacy, Department of Pharmacology, Istanbul, Turkey; sonmezdo@istanbul.edu.tr., Kaleli Durman D; Istanbul University, Faculty of Pharmacy, Department of Pharmacology, Istanbul, Turkey; deniz.kaleli@istanbul.edu.tr. |
| Abstrakt: |
Perivascular adipose tissue (PVAT) plays an important role in many physiological and pathological processes, such as regulation of vascular tone. The aim of this study is to evaluate the effects of pioglitazone on functional, structural, and biochemical properties of PVAT in an experimental model of type-2 diabetes (T2DM). T2DM was induced by high-fat-diet/low-dose-streptozotocin (HFD/STZ) in rats, and pioglitazone (20mg/kg/p.o.) was administered for 6 weeks. Changes in biochemical parameters, PVAT-mass, vascular-reactivity in thoracic-aorta as well as PVAT adipocytokine and PPARG-expression levels, and histopathology were evaluated. Pioglitazone administration improved blood glucose and lipid profiles in T2DM. Pioglitazone did not change the anticontractile effect of PVAT on aortic contractile reactivity and besides, had no influence on endothelium-dependent and -independent relaxation responses. Pioglitazone administration increased PVAT-mass and TNF-α levels while adiponectin, leptin, and IL-6 levels were unchanged. Also, a prominent increase was observed in PPARG-expression in T2DM-Pio group. Moreover, pioglitazone decreased liver steatosis, aortic wall thickening and myocardial damage whereas increased adipocyte size and adiposity in PVAT. Overall, pioglitazone treatment changed the mass and in part the inflammatory profile of PVAT but did not modify vasoreactivity in T2DM. This study provides novel findings in relationship with the adipogenic effect of pioglitazone and PVAT function. |
